Mylan seeks to make virtue from complexity of pipeline

In building an extensive pipeline of complex products that includes biosimilars, small-molecule injectables and respiratory inhalers, Mylan believes it will deliver durable cash flows and a platform for growth. Aidan Fry examines the company’s plans.